Also known as: Cotellic (brand)
Cobimetinib is a selective MEK1/2 inhibitor used in combination with vemurafenib for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. It blocks the MEK-ERK signaling pathway downstream of mutant BRAF, enhancing antitumor activity. Mediocon Inc supplies pharmaceutical-grade Cobimetinib meeting IP/BP/EP/USP standards.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | 99.0% Min. |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Related Substances | Complies |
| Microbial Limits | Complies with pharmacopoeia |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Cobimetinib (CAS 934660-93-2) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Cobimetinib is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance